October 16, 2013
12:00 pm to 1:00 pm EDT

Sponsored by

Symposium Course Description:

The clinical trial landscape is quickly evolving as the development of targeted drug therapies is now more the rule than the exception. Join one of the world’s most influential melanoma investigators, Dr. Keith Flaherty, to discuss key challenges related to melanoma clinical trials and how new approaches have the potential to offer breakthrough therapies.

Learning Objectives:

• Viewpoints on the melanoma clinical trial landscape over the next five years
• Why the advent of targeted therapies will drive trial design and implementation
• Perspectives on adaptive trial design and biomarker selection in melanoma trials

Who Should Attend:

• Clinical Trial
• Precision Medicine
• Informatics
• Clinical Business Development
• Clinical Operations

Program Agenda:

- Intro; 10-15 minutes, Larissa

- Speaker; 30 minutes, Dr. Flaherty

- Q&A; 14 minutes; Larissa and Dr. Flaherty

- Conclusion; 1 minute Larissa

Speaker Information:

Dr. Flaherty received a B.S. from Yale University and medical degree from Johns Hopkins University. He trained in internal medicine at Brigham and Women’s Hospital and completed a fellowship in medical oncology at the University of Pennsylvania. He joined the faculty in the School of Medicine at the University of Pennsylvania as an Assistant Professor of Medicine and member of the Developmental Therapeutics Program in the Abramson Cancer Center in 2002. In 2009, Dr. Flaherty moved to Massachusetts General Hospital (MGH) and Harvard Medical School to serve as Director of Developmental Therapeutics for the MGH Cancer Center.

Larissa has worked for more than a decade in the healthcare industry developing and implementing strategies and launching products focused on the needs of all industry stakeholders – biopharmaceutical companies, payers, providers, and patients. Her work has primarily been focused on clinical trials informatics and technology, with a concentration in oncology. She led one of the nation’s leading cancer clinical trials matching services and databases, and has developed and launched clinical informatics products for the pharmaceutical and biotechnology industries